Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA2 | Q9HCG7 | 18/20 | 0.57 |
| ▸ | GBA1 | P04062 | 7/20 | 0.57 |
| ▸ | GAA | P10253 | 6/20 | 0.57 |
| ▸ | UGCG | Q16739 | 3/20 | 0.57 |
| ▸ | MGAM | O43451 | 2/20 | 0.57 |
| ▸ | SI | P14410 | 2/20 | 0.57 |
| ▸ | AGL | P35573 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12325138 | 1.00 | GBA2 (0.57) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL12289779 | 1.00 | GBA2 (0.57) | GBA2GBA1GAAUGCGMGAM | |
| Piperidine SCHEMBL3381522 | 0.89 | GBA2 (0.50) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL12191646 | 0.84 | GAA (0.51) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL12289778 | 0.81 | GAA (0.55) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL12325136 | 0.81 | GAA (0.55) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL941922 | 0.81 | GAA (0.55) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL17795748 | 0.81 | GAA (0.55) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL12909425 | 0.80 | GBA2 (0.54) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL12327271 | 0.77 | GAA (0.48) | GBA2GBA1GAAUGCGMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| EP-2257286-B1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORP PLC (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| EP-2257286-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | Summit Corporation Plc (GB) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009103953-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | GBA2 508/4885GBA1 464/4885GAA 268/4885 |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | GBA2 508/4885GBA1 464/4885GAA 268/4885 |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | IRS1, SLC2A1, INSR | GBA2 508/4885GBA1 464/4885GAA 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.